论文部分内容阅读
收集复发喉癌３０例，进行回顾性临床分析，并对２５例应用流式细胞术测定细胞周期增殖活性。研究显示，术后喉癌的无瘤生存期在２～６４．５月不等，其中有８３％的患者在术后２年以内复发。复发部位在气管造口１４例（４６．７％），残喉及喉咽部包括颈段食管或舌根部各８例（２６．７％）。造口的复发与术前急诊气管切开密切相关。复发喉癌的细胞增殖指数（ＰＩ值）高于首发喉癌，而且存在高Ｓ％低Ｇ２Ｍ％和低Ｓ％高Ｇ２Ｍ％两类细胞群，这对喉癌预后评估及放疗和化疗药物的选择有一定价值
Thirty patients with recurrent laryngeal cancer were collected for retrospective clinical analysis. Twenty-five patients were tested for cell cycle proliferative activity by flow cytometry. The study showed that the postoperative laryngeal cancer-free survival in 2-64.5 months, of which 83% of patients relapsed within 2 years after surgery. The recurrent sites were 14 (46.7%) in the tracheostomy and 8 (26.7%) in the residual throat and hypopharynx including the cervical esophagus or the base of the tongue. Stoma recurrence and preoperative emergency tracheotomy are closely related. The recurrence of laryngeal cancer cell proliferation index (PI value) higher than the first laryngeal cancer, and there is a high S% low G2M% and low S% high G2M% of two cell populations, which evaluate the prognosis of laryngeal cancer and radiotherapy and chemotherapy drug selection Have a certain value